All News
IL-1 Suppression May Improve Dilated Cardiomyopathy
Interleukin-1 (IL-1) suppression helped reverse symptoms of dilated cardiomyopathy (DCM) for one patient in a case study that may implicate inflammation in the development of the condition.
Read Article
The RheumNow Week in Review – Lupus in the News (7.27.18)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Minimal Disease Activity: The Goal in PsA
The majority of patients with psoriatic arthritis (PsA) who achieved a state of minimal disease activity (MDA) after 6 months of treatment with adalimumab (Humira) maintained that response through 24 months, a large observational study found.
Read Article
Consensus Guidelines for Methotrexate in Juvenile Idiopathic Arthritis
A consensus panel was convened to develop consensus-based clinical and therapeutic recommendations for the use of methotrexate (MTX) in the management of Juvenile Idiopathic Arthritis (JIA) patients.
Read Article
Baricitinib Effective in SLE Trial
Dan Wallace and colleagues report in Lancet the results of a phase II study of the selective baricitinib, an oral selective Janus kinase (JAK1 and JAK2) inhibitor, in patients with systemic lupus erythematosus, demonstrating the efficacy and safety of JAK1/2 inhibition with baricitinib as a new potential oral therapy for SLE.
Read Article
The Lung in RA: Little Progress
The progress that has been seen in the management of many aspects of rheumatoid arthritis (RA) has not been paralleled for the pulmonary disease that remains the second most common cause of death among these patients, an Australian expert reported here at the annual meeting of the Florida Society
Read Article
Predictors of Methotrexate Non-Response
New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.
Read Article
The RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:
Read Article
Defining Refractory RA by Biologic Use
A study from the British Society for Rheumatology Biologics Register (BSRBR) has shown that biologic refractory disease is seen in at least 6% of patients who have ever received a biologic DMARD (bDMARDs).
Read Article
IL-23 Inhibitor Fails in Ankylosing Spondylitis
A study of the IL-23 risankizumab in active ankylosing spondylitis (AS) patients failed to show efficacy and did not meet primary efficacy endpoints in a 6-month trial.
Read Article
The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)
Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.
Read Article
Ixekizumab Effective in Ankylosing Spondylitis
Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.
Read Article
NPF Dietary Recommendations for Psoriatic Disease
The National Psoriasis Foundation has released dietary recommendations for adults with psoriasis and psoriatic arthritis, based on a systematic review of the current literature, with the strongest focus on weight reduction for those who are overweight or obese.
Read Article
Five Barriers to Biosimilar Adoption in the US
A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.
Read Article
Can DMARDs Delay Rheumatoid Onset?
Preclinical rheumatoid arthritis (RA) is a hot new area wherein at risk individuals (seropositive, first degree relatives of RA patients, etc.) are being studied to assess the triggers that lead to progression to RA or whether therapies can be used to avert the onset of RA.
Read Article
Enthesitis in PsA: A New Focus of Treatment?
Patients with psoriatic arthritis (PsA) whose disease manifestations include enthesitis showed significantly greater responses to interleukin (IL)-23 inhibition than to blocking tumor necrosis factor (TNF), suggesting the possibility that treatment decisions in the future might be guided by speci
Read Article
Abatacept Misses in Lupus Nephritis
Dr. Richard Furie, MD, of Northwell Health in New York, presented the findings ofa large phase III trial of abatacept (Orencia) in lupus nephritis showing the agent failed to achieve a complete renal response.
Read Article
The RheumNow Week in Review – EULAR18 Epilogue (6.22.18)
Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from RheumNow.com, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.
Read Article
Cosentyx Gets Radiographic Protection Indication for Psoriatic Arthritis
Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).
Read Article
EULAR 2018 - Day 4 Report
The EULAR 2018 wound down on Saturday with fewer oral presentations but many posters. In my last report I put together a collection of impressions and some thematic highlights not covered in previous reports.
Read Article